- Home
- CLPT vs DSGN Comparison
CLPT vs DSGN Comparison
Compare CLPT & DSGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLPT
- DSGN
- Stock Information
- Founded
- CLPT 1998
- DSGN 2017
- Country
- CLPT United States
- DSGN United States
- Employees
- CLPT N/A
- DSGN N/A
- Industry
- CLPT Medical/Dental Instruments
- DSGN Biotechnology: Pharmaceutical Preparations
- Sector
- CLPT Health Care
- DSGN Health Care
- Exchange
- CLPT Nasdaq
- DSGN Nasdaq
- Market Cap
- CLPT 412.7M
- DSGN 348.2M
- IPO Year
- CLPT N/A
- DSGN 2021
- Fundamental
- Price
- CLPT $16.72
- DSGN $4.91
- Analyst Decision
- CLPT Strong Buy
- DSGN Hold
- Analyst Count
- CLPT 3
- DSGN 3
- Target Price
- CLPT $19.67
- DSGN $7.00
- AVG Volume (30 Days)
- CLPT 179.3K
- DSGN 126.2K
- Earning Date
- CLPT 02-26-2025
- DSGN 03-18-2025
- Dividend Yield
- CLPT N/A
- DSGN N/A
- EPS Growth
- CLPT N/A
- DSGN N/A
- EPS
- CLPT N/A
- DSGN N/A
- Revenue
- CLPT $30,429,000.00
- DSGN N/A
- Revenue This Year
- CLPT $35.56
- DSGN N/A
- Revenue Next Year
- CLPT $21.86
- DSGN N/A
- P/E Ratio
- CLPT N/A
- DSGN N/A
- Revenue Growth
- CLPT 36.34
- DSGN N/A
- 52 Week Low
- CLPT $5.11
- DSGN $2.45
- 52 Week High
- CLPT $19.22
- DSGN $7.77
- Technical
- Relative Strength Index (RSI)
- CLPT 44.83
- DSGN 53.37
- Support Level
- CLPT $17.34
- DSGN $3.58
- Resistance Level
- CLPT $18.90
- DSGN $5.17
- Average True Range (ATR)
- CLPT 1.00
- DSGN 0.40
- MACD
- CLPT -0.23
- DSGN 0.11
- Stochastic Oscillator
- CLPT 15.25
- DSGN 83.65
About CLPT ClearPoint Neuro Inc.
ClearPoint Neuro Inc is a medical device company based in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, intra-procedural magnetic resonance imaging (MRI) guidance. The company's ClearPoint system, which is in commercial use, is used to perform minimally invasive surgical procedures in the brain. The company's products include the ClearPoint system, ClearPoint Services, and ClearPoint Therapeutic Solutions.
About DSGN Design Therapeutics Inc.
Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.